Lisata Therapeutics reports $351.9 million securities offering tied to business combination
A Form D filed October 2, 2026 shows Lisata sold the full offering to 20 investors with sales commissions of $2.6 million.
Lisata Therapeutics, Inc., based in Basking Ridge, New Jersey, filed a Form D notice with the Securities and Exchange Commission dated October 2, 2026, disclosing an exempt securities offering. The filing lists the date of first sale as September 17, 2026, under a new notice.1
The total offering amount and the total amount sold were both listed as $351,903,103, with $0 remaining to be sold.1 The company reported 20 total investors in the offering, including non-accredited investors.1
The securities offered include equity and a security to be acquired upon exercise of an option, warrant or other right to acquire a security.1 The filing indicates this offering was made in connection with a business combination transaction, such as a merger, acquisition or exchange offer.1
The offering claimed exemption under Rule 506(b).1 The minimum investment accepted from any outside investor was listed as $0.1
Three firms are named as recipients of sales compensation: H.C. Wainwright & Co., LLC of New York, Leerink Partners LLC of Boston, and LifeSci Capital of New York, each solicited in all states.1 Sales commissions were listed at $2,600,000, with finders' fees at $0.1 The amount of proceeds used for payments to executive officers, directors or promoters named in the filing was listed as $0.1
The filing notes the issuer's previous names as Caladrius Biosciences, Inc. and NeoStem, Inc.1, and the signature page shows the notice signed by David Mazzo, CEO, on October 2, 2026.1 The issuer size section marked "Decline to Disclose" for revenue range.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.